| Title : 68 Ga-FAPI-46 and 18 F-FDG in Advanced Metastatic Pancreatic Cancer - Kaghazchi_2022_Clin.Nucl.Med_47_e666 |
| Author(s) : Kaghazchi F , Divband G , Amini H , Adinehpour Z , Akbarian Aghdam R |
| Ref : Clin Nucl Med , 47 :e666 , 2022 |
|
Abstract :
Recently imaging with new PET radiotracers that act as fibroblast activation protein inhibitors (FAPIs) showed promising results in oncology and even nononcology imaging. Here we report a case of advanced pancreatic adenocarcinoma, imaged with both 18 F-FDG and 68 Ga-FAPI-46 PET/CT scans. The result indicated that imaging with 68 Ga-FAPI-46 showed significant improvement in detection of metastases as well as local malignancy recurrence. Moreover, the intensity and SUVs of the lesions were higher in 68 Ga-FAPI-46 scan compared with 18 F-FDG. |
| PubMedSearch : Kaghazchi_2022_Clin.Nucl.Med_47_e666 |
| PubMedID: 35714370 |
| Inhibitor | FAPI-46 |
Kaghazchi F, Divband G, Amini H, Adinehpour Z, Akbarian Aghdam R (2022)
68 Ga-FAPI-46 and 18 F-FDG in Advanced Metastatic Pancreatic Cancer
Clin Nucl Med
47 :e666
Kaghazchi F, Divband G, Amini H, Adinehpour Z, Akbarian Aghdam R (2022)
Clin Nucl Med
47 :e666